For instance, modulating lipid metabolic pathways with existing inhibitors targeting LPCAT1 or ACSL4 may disrupt aberrant lipid flux within tumor cells, impeding tumor growth and overcoming chemoresistance, while LCAT inhibitors could impair membrane integrity and energy homeostasis in HCC cells [69]. Here, LCAT is linked to hepatocellular carcinoma.